Results 91 to 100 of about 52,877 (267)

Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth

open access: yesFrontiers in Pharmacology, 2021
Colorectal cancer (CRC) is the third most common cancer worldwide and still lacks effective therapy. Ivermectin, an antiparasitic drug, has been shown to possess anti-inflammation, anti-virus, and antitumor properties. However, whether ivermectin affects
Shican Zhou   +9 more
doaj   +1 more source

Ivermectin, a potential anticancer drug derived from an antiparasitic drug

open access: yesPharmacological Research, 2020
Graphical abstract Ivermectin has powerful antitumor effects, including the inhibition of proliferation, metastasis, and angiogenic activity, in a variety of cancer cells. This may be related to the regulation of multiple signaling pathways by ivermectin
Mingyan Tang   +8 more
semanticscholar   +1 more source

Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID‐19

open access: yesJournal of Medical Virology, 2021
This trial compared the rate and time of viral clearance in subjects receiving a combination of nitazoxanide, ribavirin, and ivermectin plus Zinc versus those receiving supportive treatment.
H. Elalfy   +14 more
semanticscholar   +1 more source

Do preclinical seizure models predict success or failure in anti‐seizure drug development? A retrospective analysis of 89 compounds with divergent clinical outcomes for epilepsy

open access: yesEpilepsia, EarlyView.
Abstract Anti‐seizure medication (ASM) discovery remains a major challenge despite over 30 commercially available options. One persistent obstacle for any promising candidate compound to successfully move from preclinical study to clinical approval has been the ambiguity in preclinical model selection.
Wolfgang Löscher   +1 more
wiley   +1 more source

Parascaris spp. induced surgical colic in juvenile horses—A Scandinavian perspective

open access: yesEquine Veterinary Journal, EarlyView.
Abstract Background Parascaris spp. commonly infects foals, and high burdens can cause fatal small intestinal impactions. Progressive anthelmintic resistance poses a risk for an increase of Parascaris spp. related disease in juvenile horses. Objectives To investigate Parascaris‐related surgical intestinal lesions, with special emphasis on ascarid ...
E. Tydén   +8 more
wiley   +1 more source

Functional characterization of ivermectin binding sites in α1β2γ2L GABA(A) receptors

open access: yesFrontiers in Molecular Neuroscience, 2015
GABAA receptors (GABAARs) are the major inhibitory neurotransmitter receptors in the brain and are therapeutic targets for many indications including sedation, anesthesia and anxiolysis.
Argel eEstrada, Joe eLynch
doaj   +1 more source

Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru

open access: yesParasite Epidemiology and Control, 2023
Ivermectin has emerged as a therapeutic option for various parasitic diseases, including strongyloidiasis, scabies, lice infestations, gnathostomiasis, and myiasis.
Virgilio E. Failoc-Rojas   +6 more
doaj   +1 more source

Repurposing antimicrobial agents for neuroprotection: Mechanisms, clinical potential, and challenges

open access: yesNeuroprotection, EarlyView.
Antimicrobial agents exert neuroprotective effects through modulation of interconnected pathways. Tetracyclines, macrolides, antimalarial agents, sulfones, and antiparasitic agents suppress neuroinflammation, oxidative stress, and apoptosis while preserving mitochondrial function and neurotransmission.
Mohammad Amin Manavi   +5 more
wiley   +1 more source

Ivermectin, an unconventional agonist of the glycine receptor chloride channel [PDF]

open access: yes, 2001
The effects of the antihelmintic, ivermectin, were investigated in recombinantly expressed human alpha (1) homomeric and alpha (1)beta heteromeric glycine receptors (GlyRs), At low (0.03 muM) concentrations ivermectin potentiated the response to sub ...
Shan, Q., Lynch, J. W., Haddrill, J. L.
core   +1 more source

Advancing pharmacometrics in Africa—Transition from capacity development toward job creation

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 407-419, March 2025.
Abstract Trained pharmacometricians remain scarce in Africa due to limited training opportunities, lack of a pharmaceutical product development ecosystem, and emigration to high‐income countries. The Applied Pharmacometrics Training (APT) fellowship program was established to address these gaps and specifically foster job creation for talent retention.
Goonaseelan (Colin) Pillai   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy